In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
about
Antimicrobial resistance in Acinetobacter baumannii: From bench to bedsideEpidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipientsA focus on intra-abdominal infections.Acinetobacter baumannii: emergence of a successful pathogenTigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.Global challenge of multidrug-resistant Acinetobacter baumanniiIn vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in ItalyDaptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.What is in the pipeline for Gram-negative pathogens?Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii.In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.Establishing the role of tigecycline in an era of antimicrobial resistance.Management of meningitis due to antibiotic-resistant Acinetobacter species.Treatment options for multidrug-resistant nonfermenters.Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Combination therapy for Gram-negative bacteria: what is the evidence?Carbapenem susceptibility breakpoints, clinical implications with the moving target.Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli.In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.Investigation of in-vitro susceptibility of multidrug-resistant Acinetobacter baumannii strains isolated from clinical specimens to tigecycline.In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii groupCerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis.Breakthrough bacteremia due to extended-spectrum-β-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline.Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.In vitro antibacterial and time-kill evaluation of the Erythrina caffra Thunb. extract against bacteria associated with diarrhoea.Synergy effect of meropenem-based combinations against : a systematic review and meta-analysis
P2860
Q27024893-11432815-0B3B-450F-8553-AC83F38E9F38Q28484482-18225145-9F5C-4DE0-B78C-CFD2ACC04039Q33763449-7ED94E2D-582D-4FA8-96FA-A070C1D9A3E7Q34795807-981D1FE3-82F0-42F4-828A-4679A37BEC2EQ34803735-6EB1B43F-E48A-4255-BF53-FB4F32B2EA84Q35385769-46DBA289-49E0-4551-BA6E-335057C1AEACQ36095081-5D0E68B3-932B-492F-B630-AD66BC20B4A4Q36509591-824B921E-5438-46EC-8C8E-BE4F4EFEA163Q36967265-843554F4-48DB-490D-AA13-F82F815BFA2BQ37077619-28930E24-2D4B-43FF-B401-2F677FC6CB43Q37115690-D237358F-EF7F-4018-8000-20EEF9A57B1CQ37187728-4B47AE1C-F2E5-4F13-AFA0-3E7CCD845357Q37220041-7F2CBCB7-6132-4D32-98EF-C6140E7162E9Q37247732-8E0A9EA4-37FD-4719-8070-76CD74651B13Q37291328-48A9C743-9A5B-4452-B03A-E006B458AEF2Q37382976-622B2851-1F1C-435F-8E8E-2CA1A69D6190Q37700555-60D7CFF2-77FF-41CE-BE0E-EB81618B3CC4Q37838117-6BCBEE11-E3F4-45EE-8C86-87C24D5F31D8Q37838126-F55F0248-0A11-44E8-8782-B4C618548AE5Q37940546-A1D93300-25D6-4E50-A901-873D71CB068AQ38156194-DA527A66-00BD-44C3-8D38-49B899CF6637Q38751264-6B597DB4-3659-43AA-8404-6229D3FAA224Q41081439-CC37E702-07D3-4049-89B0-E7D83107E087Q41833657-FF65A53A-00C2-4082-8536-A5493535BDC7Q41858894-229CA38D-07A2-48CE-B4E3-7EA06662A7FEQ41882065-B9DFE456-0E9A-42BD-A89E-6177E55FD6B9Q42575942-AD1546B0-9E3B-4AC3-8882-6E5941055B19Q43152520-594C1F40-7E24-4B58-B24B-418DB39A4D5BQ43243711-0A9A8AE1-586C-4E69-95F3-9F709E17EDF0Q53791919-31994E36-E21B-402B-8105-4F95447BF024Q55651790-1F239F89-188B-439F-9CCB-11726EA899F7Q58797418-BA9105C5-39E1-441A-8670-7FC85FCB1625
P2860
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vitro activities of various ...... stant Acinetobacter baumannii.
@en
type
label
In vitro activities of various ...... stant Acinetobacter baumannii.
@en
prefLabel
In vitro activities of various ...... stant Acinetobacter baumannii.
@en
P2093
P2860
P921
P356
P1476
In vitro activities of various ...... stant Acinetobacter baumannii.
@en
P2093
Arlene Obias
Gary A Noskin
John R Warren
Michael J Postelnick
Teresa Zembower
P2860
P304
P356
10.1128/AAC.01099-06
P407
P577
2007-02-16T00:00:00Z